Amneal Biosciences

Amneal Biosciences is the specialty and institutional division of Amneal Pharmaceuticals, focusing on the development and commercialization of high-quality biosimilars and injectable medicines. The company targets complex therapeutic areas including oncology, inflammation, and infectious diseases to provide affordable treatment options for healthcare providers and patients. Their portfolio includes FDA-approved biosimilars such as Releuko, Fylnetra, and Alymsys, which compete in the biologics market. By leveraging Amneal's extensive manufacturing and R&D capabilities, the Biosciences division aims to expand access to critical therapies in the hospital and clinic settings.